Revolutionizing Disease Therapy: Everest Medicines Launches Nefecon in China’s Hainan Boao Pilot Zone for IgA Nephropathy Treatment
A Breakthrough in the Treatment of IgAN By: Anonymous Shanghai, April 23, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest,” or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that Nefecon, the first-in-disease treatment for primary immunoglobulin A nephropathy (IgAN), has been approved by…